NCT03222505

Brief Summary

The goal of this research study was to examine the immediate effects of a prototype wearable robotic stride management assist device (SMA) designed by Honda R\&D® on clinical walking performance, walking energetics, gait kinematics and corticospinal excitability in individuals with stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable stroke

Timeline
Completed

Started Jan 2010

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
7.5 years until next milestone

First Submitted

Initial submission to the registry

June 22, 2017

Completed
27 days until next milestone

First Posted

Study publicly available on registry

July 19, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

August 28, 2019

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

8.3 years

First QC Date

June 22, 2017

Results QC Date

May 17, 2019

Last Update Submit

August 15, 2019

Conditions

Keywords

StrokeGait Stride Management AssistStroke, post 1 year or longer

Outcome Measures

Primary Outcomes (2)

  • Change in Six Minute Walk Test Between Device Turned ON and OFF - Distance Traveled

    The 6 Minute Walk Test (6MWT) is a test of endurance, by measuring the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary.The distance is measured with a measuring wheel. The instructions are "Walk covering as much ground as you can in 6 min. You can stop to sit or stand if needed."

    Day 1

  • Change in Peak Treadmill (TM) Velocity Between Device Turned ON and OFF - Self Selected Walking Speed

    Peak treadmill (TM) velocity: subjects walked on motorized treadmill with harness but no Body Weight Support (BWS). Testing started at 0.5 km/h and was increased in 0.5 km/h increments every 3 minutes until peak TM speed was achieved (identified as ability to sustain speed for ≥1min without stopping the treadmill).

    Day 1

Secondary Outcomes (2)

  • Percent Change in Excitability of Transcranial Magnetic Stimulation (TMS) Rectus Femoris (RF) Between Device ON and Device OFF

    Day 1

  • Change in Percent Excitability of Transcranial Magnetic Stimulation (TMS), Dorsiflexor Tibialis Anterior (TA) Between Device ON and Device OFF

    Day 1

Study Arms (2)

Treadmill

EXPERIMENTAL
Device: Honda Stride Assist Device ONOther: No Device Worn

Overground Walking

EXPERIMENTAL
Device: Honda Stride Assist Device ONOther: No Device Worn

Interventions

Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.

Overground WalkingTreadmill

Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.

Overground WalkingTreadmill

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stroke subjects with a history of unilateral, supratentorial, ischemic or hemorrhage stroke will be recruited, with lesion location confirmed by radiographic findings.
  • All subjects who score \> 10 on the Lower Extremity Motor Score (LEMS) developed previously to measure strength in Spinal Cord Injury (SCI). For the LEMS criteria, preliminary data indicate that subjects with LEMS \< 10 in the chronic stages do not recover walking.
  • All subjects will be required to walk \> 10 m over ground without physical assistance at self-selected walking speeds ≤ 0.8 m/s using assistive devices and bracing below the knee as needed. A criterion of 0.8 m/s is utilized to target participants with limited or minimal ambulation in the community. Subjects will be further stratified into those who walk \< 0.4 m/s and \> 0.4 m/s, identified as household vs. limited community ambulators, respectively.
  • Range of motion (ankle: -10 to 30 deg, knee: 0 to 90 deg, hip: -10 to 40 deg) consistent with gait;
  • Medically stable with medical clearance to participate (absence of concurrent illness, including unhealed decubiti, infection, cardiopulmonary disease, osteoporosis, active heterotrophic ossification or peripheral nerve damage in the lower limbs, history of traumatic head injury);
  • Able to tolerate 30 minutes of upright (standing) position without orthostasis (decrease in blood pressure by 20 mmHg systolic and 10 mmHg diastolic; minimized with ambulatory population);
  • Must not be undergoing concurrent physical therapy to eliminate effects of additional interventions;
  • Patients prescribed medications for spasticity will not be excluded from participation but will be asked to maintain current levels of medication or inform the researcher if changes are necessary.

You may not qualify if:

  • Women of childbearing potential will not be excluded, although women who are pregnant will be excluded due to potential forces at trunk from body weight support or pelvic assistance;
  • Significant cardiorespiratory or metabolic disease that may limit exercise participation.
  • Weights limit \> 250 lbs (limit of most counter-weight safety systems).
  • History of previous orthopedic or neurological conditions which may impair walking.
  • Subjects with scores \< 23 on the Mini Mental Status Exam will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rehabilitation Institute of Chicago

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Results Point of Contact

Title
Arun Jayaraman, PT, PhD; Director of Max Nader Lab for Rehabilitation Technologies and Outcomes
Organization
Rehabilitation Institute of Chicago

Study Officials

  • Arun Jayaraman, PT, PhD

    Shirley Ryan AbilityLab

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 22, 2017

First Posted

July 19, 2017

Study Start

January 1, 2010

Primary Completion

May 1, 2018

Study Completion

May 1, 2018

Last Updated

August 28, 2019

Results First Posted

August 28, 2019

Record last verified: 2019-08

Locations